2024-09-24 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report

**Company Overview:** Pfizer Inc. is a global pharmaceutical company that researches, develops, manufactures, and sells medicines and vaccines.

**Performance Summary:**

* **Relative Performance:** PFE has underperformed the S&P 500 (VOO) significantly. The cumulative return for PFE is -11.31%, while the S&P 500 has returned 132.53%. This represents a massive gap of -143.84%, placing PFE at the 0th percentile of its historical performance relative to the S&P 500. 
* **Price Action:** The current price of PFE is $29.42. The stock is trading above its 5-day ($29.74) and 20-day ($29.14) moving averages, but close to its 60-day ($29.13) moving average, suggesting some short-term momentum.
* **Technical Indicators:** The RSI (54.69) indicates that the stock is not overbought or oversold, while the PPO (0.25) suggests some positive momentum.  The Delta_Previous_Relative_Divergence (-2.34) indicates a short-term downward trend. 
* **Expected Return:** The expected return for PFE is 15.25% over the next 5 years, based on current investment amounts.
* **Recent Earnings:**  PFE has been exceeding earnings expectations in recent quarters. 

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |
| 2023-08-01 | 0.67 | 0.56 |

The most recent earnings for Q2 2024 were $0.6 per share, surpassing the expected $0.458 per share. This positive trend in earnings suggests continued growth potential for the company.

**Overall Analysis:**

While PFE has underperformed the market significantly in the past, recent performance suggests that the stock may be turning a corner. Its recent earnings outperformance, combined with positive technical indicators, suggest that the company is on track for continued growth. The positive expected return and relatively neutral RSI and PPO indicators also point towards a potential for future upside.  However, investors should remain cautious due to the stock's recent relative underperformance and short-term downward trend. It is important to conduct further research and analysis before making any investment decisions. 
